Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20342670 | 0.85 | EPHX1 (0.51) | SMN1; SMN2HTTMRGPRX4RAB9AEPHX1 | |
| SCHEMBL39630 | 0.85 | FOLH1 (0.63) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL20668077 | 0.84 | PARP1 (0.52) | FOLH1SMN1; SMN2HTTRAB9AEPHX1 | |
| SCHEMBL8570687 | 0.82 | SMN1; SMN2 (0.42) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL39841 | 0.82 | SMN1; SMN2 (0.56) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL9976790 | 0.81 | FOLH1 (0.59) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL27326766 | 0.81 | FOLH1 (0.59) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL28544976 | 0.81 | FOLH1 (0.59) | FOLH1SMN1; SMN2HTTMRGPRX4AR | |
| SCHEMBL20130636 | 0.81 | SLC7A5 (0.56) | SMN1; SMN2MRGPRX4RAB9A | |
| SCHEMBL6011693 | 0.81 | LOXL2 (0.66) | FOLH1SMN1; SMN2MRGPRX4RAB9AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2023-01-19 | — | — | US | disclosed |
| WO-2020167952-A1 | MAT2A INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20180078552-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | PURDUE RESEARCH FOUNDATION | 2018-03-22 | — | — | US | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078552-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | FOLH1 2731/4885SMN1; SMN2 666/4885HTT 276/4885 |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | FOLH1 2838/4885SMN1; SMN2 1036/4885HTT 3480/4885 |
| US-20230018687-A1 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | SYK, BTK, CD47 | FOLH1 2731/4885SMN1; SMN2 666/4885HTT 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.